BiotechTube
Genomtec

Genomtec

Wrocław, Poland· Est.
genomtec.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

Genomtec is an emerging player in the point-of-care molecular diagnostics space, with a flagship CE-IVD marked product for respiratory infections. The company is actively pursuing growth through capital raises, M&A activities, and expansion into Asian markets, as indicated by recent news. Founded in 2022 and based in Wrocław, Poland, it has garnered significant recognition through various innovation awards and competitions, signaling strong technological promise.

Infectious Diseases

Technology Platform

Genomtec ID: A mobile, point-of-care platform for genetic diagnostics utilizing isothermal amplification for rapid, multiplexed pathogen detection without the need for a central lab.

Funding History

2
Total raised:$2M
Grant$500K
Seed$1.5M

Opportunities

First-mover advantage in Europe with a CE-IVD marked mobile POC molecular diagnostic for respiratory infections.
Significant growth potential through expansion into the large Asian market, facilitated by prior competition wins and government interest in China.
The platform's modular design allows for rapid expansion into new high-volume diagnostic panels beyond respiratory diseases.

Risk Factors

Intense competition from large diagnostics corporations and other startups in the POC molecular space.
Execution risks associated with commercializing a novel platform, securing reimbursement, and integrating potential acquisitions.
Reliance on a successful capital raise to fund its growth strategy, with associated dilution and integration risks.

Competitive Landscape

The point-of-care molecular diagnostics market is highly competitive, dominated by global players like Abbott (ID NOW), Cepheid (GeneXpert), and Roche (Cobas Liat). Genomtec's differentiation lies in its emphasis on a 'mobile' platform and its specific CE-marked multiplex respiratory panel, claiming a unique position in Europe. However, it must compete on price, ease-of-use, test menu breadth, and commercial reach against these well-established incumbents.

More companies in Diagnostics & Precision Medicine →More companies in Poland →